Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Astrocytoma 2Adenomatous Polyposis Coli 2Neoplasms 1Melanoma 1Glioma 1Glioblastoma 1Colonic Polyps 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 17Radiotherapy 8Surgical Procedures, Operative 6Flucytosine 6vocimagene amiretrorepvec 5IL13-PE38 5Lomustine 4Valacyclovir 3Radiation 3Corticotropin-Releasing Hormone 3Chlorotoxin 3Carmustine 3Bevacizumab 3vorasidenib 2trametinib 2tovorafenib 2regorafenib 2pembrolizumab 2paclitaxel-Angiopep-2 conjugate 2dabrafenib 2Trabedersen 2OKN 007 2Nivolumab 2Everolimus 2Eflornithine 2Drug Delivery Systems 2Carboplatin 2Cancer Vaccines 2Adjuvants, Immunologic 2trastuzumab deruxtecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Astrocytoma × Eflornithine × Clear all
NCT05879367 2025-06-25

Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

Orbus Therapeutics, Inc.

Phase 1 Recruiting
66 enrolled
CNS

Astrocytoma, Glioblastoma

NCT02796261 2022-01-21

STELLAR

Orbus Therapeutics, Inc.

Phase 3 Unknown
343 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡